WebThe recombinant humanized monoclonal antibody eculizumab (Soliris(®)) is a complement inhibitor that is indicated for use in the treatment of atypical haemolytic uraemic syndrome (aHUS). This article reviews the clinical efficacy and tolerability of eculizumab in the treatment of patients with aHUS, as well as summarizing its pharmacological properties. WebSoliris eculizumab aHUS 300 mg vials 25682-0001-01 4 vials/120 ml MG/NMOSD 300 mg vials 25682-0001-01 4 vials/120ml PNH 300 mg vials 25682-0001-01 3 vials/90ml . Background . Eculizumab is a monoclonal antibody that binds with high affinity to compliment protein C5, which inhibits its cleavage to C5a
Soliris® (Eculizumab) – UnitedHealthcare West Medical Management Guideline
WebFeb 17, 2024 · Soliris is composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148 kDa. Soliris is … WebAug 31, 2024 · The most common side effects in people with NMOSD treated with SOLIRIS include: common cold (upper respiratory infection) pain or swelling of your nose or throat (nasopharyngitis) diarrhea. back pain. joint pain (arthralgia) throat irritation ( pharyngitis) bruising ( contusion) dizziness. blackfoot whiskey train
Eculizumab (Soliris) - Side Effects, Interactions, Uses, Dosage ...
Eculizumab, sold under the brand name Soliris among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis, and neuromyelitis optica. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Ecul… WebSoliris, how these risks can be minimised, and how more information will be obtained about risks and uncertainties (missing information) of Soliris. Summary of product … WebAug 27, 2024 · BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission (EC) has approved the extension of the current marketing authorization of SOLIRIS ® (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti … game of thrones history timeline